Department of Breast Surgery, Maternal and Child, Center for Prevention and Cure of Breast Diseases, Haidian Maternal and Child Health Hospital, Haidian District, Beijing, China.
Medicine (Baltimore). 2022 Jul 1;101(26):e29761. doi: 10.1097/MD.0000000000029761.
Lactational mastitis and breast abscess cause trouble for women. It has been shown that oral probiotics can improve breast microecology, thus alleviating inflammatory responses. Our study aims to understand the long-term effect of Lactobacillus fermentum CECT5716 on patients with lactational breast abscess after needle aspiration.
Data continued in a randomized controlled study of 101 subjects with lactational abscess from 12 hospitals were included. They were randomly divided into an experimental group and a control group. After needle aspiration treatment, the experimental group was orally administrated with L fermentum CECT5716 for 4 consecutive weeks, while the control group was treated with maltodextrin in the same way). In the third month after randomized controlled trial, the subjects were followed up by an online questionnaire investigation. The observation indexes included the relief of breast pain, recurrence of mastitis from the end of oral administration to the follow-up, and the effect on continuing breastfeeding.
A total of 101 patients were enrolled and 83 valid questionnaires were received during follow-up, including 40 in the experimental group and 43 in the control group. The rate of stop breastfeeding due to recurrence of mastitis was 2.5% (1/40) in the experimental group and 18.6% (8/43) in the control group, with a statistically significant difference (odds ratio = 0.112, 95% confidence interval: 0.013-0.942, P < .05). The rate of stop breastfeeding was 10% (4/40) in the experimental group and 25.6% (11/43) in the control group, without significant difference. The pain relief rate in the experimental group was 80% (32/40), which showed no significant difference from that in the control group, that is, 72.1% (31/43). The recurrence rate of mastitis in the experimental group was 20% (8/40), which was not significantly different from that in the control group, that is, 16.3% (7/43).
In lactating women with a history of breast abscess, oral L fermentum CECT5716 may reduce the risk of stop breastfeeding due to recurrence of mastitis.
哺乳期乳腺炎和乳房脓肿给女性带来困扰。有研究表明，口服益生菌可以改善乳房微生态，从而缓解炎症反应。我们的研究旨在了解乳酸发酵乳杆菌 CECT5716 对哺乳期乳房脓肿经针吸治疗后的患者的长期影响。
纳入了 12 家医院 101 例哺乳期脓肿患者的随机对照研究中的连续数据。他们被随机分为实验组和对照组。针吸治疗后，实验组连续 4 周口服 L 发酵乳杆菌 CECT5716，对照组则以麦芽糊精同样处理。在随机对照试验结束后的第三个月，通过在线问卷调查对受试者进行随访。观察指标包括乳房疼痛缓解、口服结束至随访期间乳腺炎复发、对继续母乳喂养的影响。
共纳入 101 例患者，随访期间收到 83 份有效问卷，其中实验组 40 例，对照组 43 例。实验组因乳腺炎复发而停止母乳喂养的比例为 2.5%（1/40），对照组为 18.6%（8/43），差异有统计学意义（比值比=0.112，95%置信区间：0.013~0.942，P<0.05）。实验组因其他原因停止母乳喂养的比例为 10%（4/40），对照组为 25.6%（11/43），差异无统计学意义。实验组疼痛缓解率为 80%（32/40），与对照组的 72.1%（31/43）差异无统计学意义。实验组乳腺炎复发率为 20%（8/40），与对照组的 16.3%（7/43）差异无统计学意义。
在有哺乳期乳腺炎病史的哺乳期妇女中，口服 L 发酵乳杆菌 CECT5716 可能降低因乳腺炎复发而停止母乳喂养的风险。
